Document:

<PAGE>

                                                                   Exhibit 10.44

                                FOURTH AMENDMENT
                                       TO
                                 ALLERGAN, INC.
                      EXECUTIVE DEFERRED COMPENSATION PLAN
                            (RESTATED JANUARY 1, 2000)

     The ALLERGAN, INC. EXECUTIVE DEFERRED COMPENSATION PLAN (the "Plan") is
hereby amended as follows:

1.   Article I of the Plan is amended by renumbering Section 1.3 as Section 1.4
     and adding the following Section 1.3:

                 1.3   Spin-off of Advanced Medical Optics, Inc. In connection
           with the distribution of the stock of Advanced Medical Optics, Inc.
           ("AMO") by Allergan to its stockholders (the "AMO Spin-Off") and,
           effective as of the AMO Spin-Off Date: (i) AMO Employees shall cease
           to be eligible to participate in the Plan and their Deferral
           Elections for the 2002 Plan Year shall be terminated, and (ii) the
           assets attributable to, and the liabilities relating to, arising out
           of, or resulting from the Deferral Accounts of AMO Employees shall be
           transferred to the Advanced Medical Optics, Inc. Deferred
           Compensation Plan. The "AMO Spin-off Date" shall be June 29, 2002 and
           "AMO Employees" shall be those individuals whose employment is
           transferred from Allergan to AMO in connection with the AMO Spin-off,
           as reflected in the payroll records of Allergan or in the Employee
           Matters Agreement entered into between Allergan and AMO.

2.   The last sentence of Section 14.2 is amended as follows:

                 In addition, notwithstanding the preceding provisions of this
           Section 14.2, a Change in Control shall not be deemed to have
           occurred, (i) if the Person described in the preceding provisions of
           this Section 14.2 becomes a Beneficial Owner of more than the
           permitted amount of outstanding securities as a result of the
           acquisition of voting securities by Allergan which, by reducing the
           number of voting securities outstanding, increases the proportional
           number of shares beneficially owned by such Person, provided, that if
           a Change in Control would occur but for the operation of this
           sentence and such Person becomes the Beneficial Owner of any
           additional voting securities (other than through the exercise of
           options granted under any stock option plan of the Company or through
           a stock dividend or stock split), then a Change in Control shall
           occur, and (ii) upon the distribution of the stock of Advanced
           Medical Optics, Inc. on June 29, 2002 by Allergan to its
           stockholders.

<PAGE>

     IN WITNESS WHEREOF, Allergan, Inc. hereby executes this Fourth Amendment to
the Allergan, Inc. Executive Deferred Compensation Plan on this 26th day of
June, 2002.

ALLERGAN, INC.

BY: /s/ Eric Brandt
    -----------------------------------
    Eric Brandt
    Corporate Vice President

                                       2<PAGE>

                                                                   Exhibit 10.45

                                THIRD AMENDMENT
                                       TO
                                 ALLERGAN, INC.
                      SUPPLEMENTAL EXECUTIVE BENEFIT PLAN
                                (RESTATED 1996)

     The ALLERGAN, INC. SUPPLEMENTAL EXECUTIVE BENEFIT PLAN (the "Plan") IS
hereby amended as follows:

1.   Article I of the Plan is amended by renumbering Section 1.4 as Section 1.5
     and adding the following Section 1.4:

                 1.4 Spin-off of Advanced Medical Optics, Inc. In connection
           with the distribution of the stock of Advanced Medical Optics, Inc.
           ("AMO") by Allergan to its stockholders (the "AMO Spin-off") and,
           effective as of the AMO Spin-off Date: (i) AMO Employees shall cease
           to be eligible to participate in the Plan and shall cease to accrue
           benefits under the Plan, and (ii) the assets attributable to, and the
           liabilities relating to, arising out of, or resulting from the
           benefits of AMO Employees shall remain with the Plan and shall be
           payable from the Plan to AMO Employees at such times and in such
           forms as permitted under the Plan. The "AMO Spin-off Date" shall be
           June 29, 2002 and "AMO Employees" shall be those individuals whose
           employment is transferred from Allergan to AMO in connection with the
           AMO Spin-off, as reflected in the payroll records of Allergan or in
           the Employee Matters Agreement entered into between Allergan and AMO.

2.   The last sentence of Section 5.4 is amended as follows:

                 In addition, notwithstanding the preceding provisions of this
           Section 5.4, a Change in Control shall not be deemed to have
           occurred, (i) if the Person described in the preceding provisions of
           this Section 5.4 becomes a Beneficial Owner of more than the
           permitted amount of outstanding securities as a result of the
           acquisition of voting securities by the Sponsor which, by reducing
           the number of voting securities outstanding, increases the
           proportional number of shares beneficially owned by such Person,
           provided, that if a Change in Control would occur but for the
           operation of this sentence and such Person becomes the Beneficial
           Owner of any additional voting securities (other than through the
           exercise of options granted under any stock option plan of the
           Sponsor or through a stock dividend or stock split), then a Change in
           Control shall occur, and (ii) upon the distribution of the stock of
           Advanced Medical Optics, Inc. on June 29, 2002 by the Sponsor to its
           stockholders.

<PAGE>

     IN WITNESS WHEREOF, Allergan, Inc. hereby executes this Third Amendment
to the Allergan, Inc. Supplemental Executive Benefit Plan on this 26th day of
June, 2002.

ALLERGAN, INC.

BY: /s/ Eric Brandt
    -----------------------------------
    Eric Brandt
    Corporate Vice President

                                       2<PAGE>

                                                                   Exhibit 10.46
                                                                  DRAFT 06/19/02

                                THIRD AMENDMENT
                                       TO
                                 ALLERGAN, INC.
                      SUPPLEMENTAL RETIREMENT INCOME PLAN
                                (RESTATED 1996)

     The ALLERGAN, INC. SUPPLEMENTAL RETIREMENT INCOME PLAN (the "Plan") is
hereby amended as follows:

1.   Article I of the Plan is amended by renumbering Section 1.4 as Section 1.5
     and adding the following Section 1.4:

                 1.4   Spin-off of Advanced Medical Optics, Inc. In connection
           with the distribution of the stock of Advanced Medical Optics, Inc.
           ("AMO") by Allergan to its stockholders (the "AMO Spin-off") and,
           effective as of the AMO Spin-off Date: (i) AMO Employees shall cease
           to be eligible to participate in the Plan and shall cease to accrue
           benefits under the Plan, and (ii) the assets attributable to, and the
           liabilities relating to, arising out of, or resulting from the
           benefits of AMO Employees shall remain with the Plan and shall be
           payable from the Plan to AMO Employees at such times and in such
           forms as permitted under the Plan. The "AMO Spin-off Date" shall be
           June 29, 2002 and "AMO Employees" shall be those individuals whose
           employment is transferred from Allergan to AMO in connection with the
           AMO Spin-off, as reflected in the payroll records of Allergan or in
           the Employee Matters Agreement entered into between Allergan and AMO.

2.   The last sentence of Section 5.4 is amended as follows:

                 In addition, notwithstanding the preceding provisions of this
           Section 5.4, a Change in Control shall not be deemed to have
           occurred, (i) if the Person described in the preceding provisions of
           this Section 5.4 becomes a Beneficial Owner of more than the
           permitted amount of outstanding securities as a result of the
           acquisition of voting securities by the Sponsor which, by reducing
           the number of voting securities outstanding, increases the
           proportional number of shares beneficially owned by such Person,
           provided, that if a Change in Control would occur but for the
           operation of this sentence and such Person becomes the Beneficial
           Owner of any additional voting securities (other than through the
           exercise of options granted under any stock option plan of the
           Sponsor or through a stock dividend or stock split), then a Change in
           Control shall occur, and (ii) upon the distribution of the stock of
           Advanced Medical Optics, Inc. on June 29, 2002 by the Sponsor to its
           stockholders.

<PAGE>

                                                                  DRAFT O6/19/02

     IN WITNESS WHEREOF, Allergan, Inc. hereby executes this Third Amendment to
the Allergan, Inc. Supplemental Retirement Income Plan on this 26th day of June,
2002.

ALLERGAN, INC.

BY: /s/ Eric Brandt
    -----------------------------------
    Eric Brandt
    Corporate Vice President

                                        2<PAGE>

                                                                   Exhibit 10.35

         Wyeth Research                              L Patrick Gage, Ph.D.
         PO. Box 8299                                President
         Philadelphia. PA 19101-8299                 484 865 5870 tel
                                                     484 865 9094 fax

Wyeth

         May 29, 2002

         Michel de Rosen
         President and Chief Executive Officer
         ViroPharma Incorporated
         405 Eagleview Boulevard
         Exton, PA 19341
                                 RE:  Extension of Screening Phase

         Dear Michel:

                  As you are aware, Section 4.3 of the Collaboration and License
         Agreement (the "Agreement") dated December 9,1999, by and between
         ViroPharma Incorporated, (hereinafter, "ViroPharma") and Wyeth
         (formerly, "American Home Products Corporation") acting through its
         Wyeth Pharmaceuticals Division (formerly, its "WyethAyerst Laboratories
         Division") (hereinafter, "Wyeth"), contemplates that the parties may
         agree to extend the Screening Phase of the Research Program by one (1)
         additional year.

                  Notwithstanding the one (1) year limitation set forth in
         Section 4.3 of the Agreement, this letter serves to represent the
         agreement of ViroPharma and Wyeth to extend the Screening Phase of the
         Research Program under the Agreement by a period of two (2) years
         following the expiration of the Initial Term of the Screening Phase,
         such that the Screening Phase will now expire on the fifth (5th)
         anniversary of the Effective Date of the Agreement. Such extension
         shall be under the same terms and conditions as have been applicable to
         the Initial Term of the Screening Phase provided, however, that the
         date on which a Party may first exercise its right of Termination for
         Convenience pursuant to Section 11.5 of the Agreement shall be
         extended for one (1) year, rather than two (2) years, as a result of
         this two-year extension of the Screening Phase, and Section 11.5.1 is
         hereby amended to read as follows:

                  "11.5.1 Right to Terminate. After the first anniversary of the
                  expiration of the Initial Term of the Screening Phase, either
                  Party may terminate this Agreement upon one hundred eighty
                  (180) days prior written notice to the

<PAGE>

         Michel de Rosen
         ViroPharma Incorporated
         May 29, 2002
         Page 2 of 2

                  other Party (a "Termination for Convenience")."

                  All capitalized terms used in this letter that are not defined
         in this letter shall have the meanings ascribed to them in the
         Agreement. Except as expressly modified hereby, all provisions of the
         Agreement shall not be affected hereby and shall remain in full force
         and effect. In particular, I wish to point out that, in accordance with
         Sections 9.5 of the Agreement, no public announcement of the matters
         agreed to in this letter agreement may be made by either Party without
         the other Party's prior written approval and that any announcements to
         be made as provided in Section 9.3 still require review of each of the
         Parties. If ViroPharma wishes to make any such announcement, please
         submit it to Wyeth for review and approval as soon as possible so as to
         allow for sufficient opportunity to have it submitted through our
         approval process.

                  Please indicate your acceptance of and agreement to the terms
         and conditions set forth above by signing the enclosed duplicate
         original of this letter agreement and returning it to me.

                                                     Regards,

                                                     /s/ L. Patrick Gage, Ph.D.

         cc:   A. Cohn
               M. Lee

         AJC

         ACKNOWLEDGED, ACCEPTED AND AGREED

         VIROPHARMA INCORPORATED

         By:   /s/ Michel de Rosen

               Michel de Rosen
               President and Chief Executive Officer

         Date: June 6, 2002

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]